HTA64 Surrogate Endpoints Used in NICE Technology Appraisals for Oncology and Non-Oncology Indications, 2022–23
Dec 1, 2023, 00:00
10.1016/j.jval.2023.09.1749
https://www.valueinhealthjournal.com/article/S1098-3015(23)04879-9/fulltext
Title :
HTA64 Surrogate Endpoints Used in NICE Technology Appraisals for Oncology and Non-Oncology Indications, 2022–23
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)04879-9&doi=10.1016/j.jval.2023.09.1749
First page :
Section Title :
Open access? :
No
Section Order :
11191